← All trials
NCT04777851
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Dec 15, 2024
- Completion date
- May 15, 2025
- First posted
- Mar 2, 2021
- Last posted
- Sep 23, 2021
- Enrollment
- 496
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Translational Research in OncologyLead sponsor
- BayerCollaborator
- Johannes Gutenburg UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.